Pfizer is due to release its earnings in the US tonight and the stage is set for what's been dubbed "record-shattering revenues", and analysts believe two new products will bring sales beyond the US$1 billion mark. But can the pharmaceutical giant sustain these gains in the medium to long term? Michelle Martin finds out.

Market View: Lululemon Plunges, S-REITs vs Banks, Nvidia’s $13B AI Bet & Why the Dutch Are Moving Gold
12:46

Advanced Diagnostic Tests the Super Health-Conscious are opting for
25:39

Money and Me: BTO Ceiling at $16K, More Homes Coming: Is Singapore Turning Into a Buyer’s Market?
21:32